论文部分内容阅读
目的:探讨布地奈德联合福莫特罗干粉剂治疗中、重度支气管哮喘临床治疗效果。方法:选取2017年2月到2017年9月间因中、重度支气管哮喘进入我院接受治疗的患者30例,分为观察组15例以布地奈德联合福莫特罗干粉剂治疗,对照组15例以布地奈德单独治疗,对照2组患者治疗后,哮喘控制情况,观察2组治疗前后四周和十二周[第一秒用力呼气容积EFV_1,FEV_1占预计值百分FEV_1%,最大呼气峰流速值PEF,PEF占预计值百分PEF_1%,肺功能指标。行统计学分析。结果:治疗后,观察组哮喘控制情况均为(21.8±3.2)分,80.0%总有效率,明显优于对照组,差异具有统计学意义,P<0.05。观察组肺功能各项指标优于对照组,P<0.05。结论:布地奈德联合福莫特罗干粉剂治疗中、重度支气管哮喘可以有效控制哮喘情况,值得推广。
Objective: To investigate the clinical efficacy of budesonide combined with formoterol powder in the treatment of moderate and severe bronchial asthma. Methods: From February 2017 to September 2017, 30 patients with moderate and severe bronchial asthma admitted to our hospital were selected and divided into observation group (15 cases) and budesonide combined with formoterol powder Cases of budesonide alone treatment, control two groups of patients after treatment, asthma control, two weeks before and after treatment and two weeks of observation [first second forced expiratory volume EFV_1, FEV_1 accounted for the expected percentage FEV_1%, the maximum call Peak flow velocity PEF, PEF accounted for the expected percentage PEF_1%, pulmonary function indicators. Line statistical analysis. Results: After treatment, the asthma control in the observation group was (21.8 ± 3.2) points, 80.0% of the total effective rate, which was significantly better than the control group, the difference was statistically significant, P <0.05. The indexes of lung function in the observation group were better than those in the control group (P <0.05). Conclusion: The combination of budesonide and formoterol in the treatment of moderate and severe bronchial asthma can effectively control asthma and is worth promoting.